Background: Immune thrombocytopenia (ITP) is an autoimmune mediated hemorrhagic disease characterized by thrombocytopenia. Platelet specific antibodies play a key role in platelet destruction.

Aims: This study was aimed to determine whether platelet specific antibodies (including anti-GPIIb/IIIa, anti-GPIb/IX and anti-GPIa/IIa antibodies) are related to the first-line treatment effect of newly diagnosed pediatric ITP.

Methods: This study retrospectively analyzed 154 newly diagnosed ITP patients from October 2016 to September 2021 in Beijing Children’s Hospital. These patients were treated with glucocorticoids and/or intravenous immunoglobulin (IVIG). And platelet counts were detected one week and one month after treatment. Platelet specific antibodies were detected by PAKAUTO.

Results: When the antibody levels were divided into positive and negative, children with positive anti-GPIb/IX antibody responded worse than those with negative anti-GPIb/IX antibody at both one week and one month (Z=-2.565, P=0.010; Z=-2.579, P=0.010). When the antibody titer ratio was used to reflect the antibody levels, there was no significant difference between platelet specific antibodies and the first-line treatment effect in newly diagnosed pediatric ITP.

Conclusion(s): Anti-GPIb/IX antibody is a sign of worse response in newly diagnosed pediatric ITP.

« Back to ISTH 2022 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/the-predictive-value-of-platelet-specific-antibodies-for-the-first-line-treatment-effect-in-newly-diagnosed-pediatric-itp/